Extended in vivo activity of VRC01 HIV-1 prophylaxis entails initial protective efficacy and subsequent breakthrough infections
The two parallel Antibody Mediated Prevention (AMP) prevention efficacy trials evaluated whether intravenous infusion of the anti-CD4 binding site broadly neutralizing antibody VRC01 prevents HIV-1 acquisition. Here we analyzed HIV-1 acquisition in AMP through the Week 104 final study visit. Against viruses considered...